Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.374
Neutral
RSI(14)
55.548
Neutral
STOCH(KDJ)(9,3,3)
78.597
Neutral
ATR(14)
0.938
Low Volatility
CCI(14)
117.591
Buy
Williams %R
22.543
Buy
TRIX(12,20)
-0.060
Sell
StochRSI(14)
84.575
Overbought
Search
SI-BONE Inc
SIBNAdd to Watchlist
14.160USD
-0.440-3.01%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
627.99MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of SI-BONE Inc
Currency: USD Updated: 2026-05-15Key Insights
SI-BONE Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
SI-BONE Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
SI-BONE Inc Highlights
StrengthsRisks
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.67% year-on-year.
Undervalued
The company’s latest PE is -36.86, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.75M shares, decreasing 4.78% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.97K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.76.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
24.000
Target Price
+64.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of SI-BONE Inc is 7.12, ranking 85 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 52.59M, representing a year-over-year increase of 11.20%, while its net profit experienced a year-over-year increase of 33.75%.
Score
Financials
8.74
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.48
Operational Efficiency
7.03
Growth Potential
7.20
Shareholder Returns
7.15
SI-BONE Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of SI-BONE Inc is 7.11, ranking 121 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -36.86, which is -80.75% below the recent high of -7.10 and -13.89% above the recent low of -41.98.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 9/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of SI-BONE Inc is 8.44, ranking 32 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 25.00, with a high of 32.00 and a low of 21.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
24.000
Target Price
+64.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
116
Total
6
Median
9
Average
Company name
Ratings
Analysts
SI-BONE Inc
SIBN
9
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of SI-BONE Inc is 9.02, ranking 21 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 15.57 and the support level at 12.11, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
13.686
Buy
MA10
13.354
Buy
MA20
13.276
Buy
MA50
13.300
Buy
MA100
15.251
Sell
MA200
15.852
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of SI-BONE Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 103.63%, representing a quarter-over-quarter decrease of 3.16%. The largest institutional shareholder is Steven Cohen, holding a total of 745.97K shares, representing 1.68% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SI-BONE Inc is 6.59, ranking 55 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.70
VaR
+4.77%
240-Day Maximum Drawdown
+45.75%
240-Day Volatility
+50.42%
Return
Best Daily Return
60 days
+19.72%
120 days
+19.72%
5 years
+19.72%
Worst Daily Return
60 days
-6.21%
120 days
-12.57%
5 years
-24.33%
Sharpe Ratio
60 days
-0.36
120 days
-0.78
5 years
+0.04
Risk Assessment
Maximum Drawdown
240 days
+45.75%
3 years
+57.57%
5 years
+59.83%
Return-to-Drawdown Ratio
240 days
-0.54
3 years
-0.28
5 years
-0.15
Skewness
240 days
+1.14
3 years
+0.70
5 years
+0.24
Volatility
Realised Volatility
240 days
+50.42%
5 years
+57.66%
Standardised True Range
240 days
+5.00%
5 years
+6.18%
Downside Risk-Adjusted Return
120 days
-127.35%
240 days
-127.35%
Maximum Daily Upside Volatility
60 days
+52.76%
Maximum Daily Downside Volatility
60 days
+38.47%
Liquidity
Average Turnover Rate
60 days
+1.70%
120 days
+1.46%
5 years
--
Turnover Deviation
20 days
+77.47%
60 days
+55.46%
120 days
+33.51%
Peer Comparison
Healthcare Equipment & Supplies
SI-BONE Inc
SIBN
8.00 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
